ATS Stat

HomeATS Stat ▶ Stat May 2, 2018
Stat May 2, 2018


Submit Your Manuscript for a Focused Issue of AJRCMB

The American Thoracic Society is now accepting original research contributions and concise translational reviews for an issue of the American Journal of Respiratory Cell and Molecular Biology (AJRCMB), to be published in 2019. This issue will focus on cellular senescence in lung biology and disease, and single cell approaches to lung disease. All submissions must be received by Monday, Oct. 1, 2018.
Submission Guidelines

  • All submissions should conform to AJRCMB’s formatting requirements as outlined in the Instructions for Contributors.
  • Online submission cover letters should mention your interest in appearing in the focused issue. Please specify which topic.

Authors with questions can contact Marc Bendian.


Now Accepting Letters of Intent

The ATS Foundation Research Program 2018-2019 grant cycle is now open! This year’s portfolio includes 15 unrestricted grants as well as the following specific grant opportunities:   

  • alpha-1 antitrypsin  
  • idiopathic pulmonary fibrosis (IPF)   
  • nasal high flow (NHF)   
  • neuroendocrine hyperplasia of infancy (NEHI)   
  • non-tuberculous mycobacteria (NTM)   
  • Oregon based researchers  
  • pulmonary arterial hypertension (PAH)   
  • sarcoidosis   
  • sleep disordered breathing and PAP therapy

For more information on the current opportunities, please visit our portfolio. If you have questions about the grant program, eligibility, or application process, please refer to our FAQ. The deadline for letters of intent is 11:59 pm ET on June 12, 2018. Spread the word and encourage investigators in your division to apply. Begin your application today!


Road Maps to Navigate the Conference

Given the size and complexity of the International Conference, the ATS creates a number of “Road Maps” to help highlight sessions and other learning opportunities within a given area of interest or audience type. These include:

  • Road Map for Beating Burnout
  • Road Map for Early Career Professionals
  • Road Map for Medical Educators
  • Rare Lung Disease Guide
  • Highlights for Clinicians
  • Final Program 

These road maps can be accessed via the conference website or the conference app (under the Sessions & Abstracts tile), which is now available for download in the App Store or Google Play.


Now Available: ATS 2018 App

For information at your fingertips, download the conference app from the App Store or Google Play.  With this tool, you can:

  • Build your itinerary.
  • Participate in in-session Q&As using ARS (Audience Response System).
  • Learn about special events.
  • Browse sessions and speakers.
  • Map your trip to the Exhibit Hall.
  • View the wide array of available educational opportunities.
  • Receive important updates.
  • Connect and chat with other attendees.
  • Scan colleagues’ badges to quickly exchange contact information.

Together, these and other capabilities make the ATS 2018 conference app a must-have tool. Visit the App Store or Google Play to download it today.

Supported by Gilead Sciences, Inc.


World Asthma Day

Yesterday, May 1, marked the 20th annual World Asthma Day. The American Thoracic Society joined the Global Initiative for Asthma (GINA) and other founding members of the Forum of International Respiratory Societies (FIRS) in recognizing this year’s theme, “Never too early, never too late. It’s always the right time to address airways disease.”

According to WHO estimates, 235 million people suffer from asthma, which can cause wheezing, breathlessness, chest tightness, and coughing. Although asthma cannot be cured, it is possible to control it. It is the most common chronic disease among children; more children (55 percent) than adults (49 percent) had at least one asthma attack in 2012.

Asthma is under-diagnosed and under-treated. This year’s theme is a call to action for both patients and health care providers worldwide to evaluate symptoms regardless of when they occur, and take actions to ensure that the asthma is controlled.